Conference Call to be held the same day at 9:00am Eastern Time
ATLANTA, April 30, 2024 (GLOBE NEWSWIRE) — Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will report first quarter financial results on May 14, 2024, prior to the market open.
Management will host a conference call at 9:00 AM ET on the same day, to review financial results and provide an update on corporate developments. Following management’s formal remarks there will be a question-and-answer session.
Participants can register for the conference by navigating to
https://dpregister.com/sreg/10188147/fc37036c2f
Please note that registered participants will receive their dial-in number upon registration and will dial directly into the call without delay. Those without internet access or who are unable to pre-register may dial in by calling 1-844-839-2190 (domestic) or 1-412-717-9583 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Alimera Sciences call.
The conference call will also be available through live webcast at https://event.choruscall.com/mediaframe/webcast.html?webcastid=rPb7Xp5V and is also available through the company’s website.
A webcast replay of the call will be available approximately one hour after the end of the call through August 14, 2024. The webcast replay can be accessed through the above links or by calling 1-877-344-7529 (domestic) or 1-412-317-0088 (toll) or via an international dial-in number at: https://services.choruscall.com/ccforms/replay.html. Please use the following replay code 9720210. The telephonic replay will be available until May 28, 2024.
About Alimera Sciences, Inc.
Alimera Sciences is a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer. For more information, please visit www.alimerasciences.com.
For press inquiries: | For investor inquiries: |
Jules Abraham | Scott Gordon |
for Alimera Sciences | for Alimera Sciences |
917-885-7378 | scottg@coreir.com |
julesa@coreir.com |
PALO ALTO, Calif., Nov. 22, 2024 /PRNewswire/ -- Aulisa® Medical USA, Inc., a leader in…
NEW YORK, Nov. 22, 2024 /PRNewswire/ -- Report on how AI is redefining market landscape -…
Vancouver, British Columbia--(Newsfile Corp. - November 22, 2024) - DEFENCE THERAPEUTICS INC. (CSE: DTC) (OTCQB:…
3,250 InsuJet Starter Packs Being Delivered to Pharmacies Across CanadaToronto, Ontario--(Newsfile Corp. - November 22,…
The new app allows users to browse services, book IV therapy, manage appointments, purchase packages,…
PHILADELPHIA, Nov. 22, 2024 /PRNewswire/ -- Independence Blue Cross (IBX) is implementing the Epic Payer Platform…